Panorex study whets appetite for more data

After five years, Centocor Inc. presented encouraging findings from its study of the Panorex monoclonal antibody in colorectal cancer, but indications are that both the company and clinicians will want to see the results replicated in a larger study.

As of now, the company only plans to use the data for a January 1994 marketing filing in Germany.

CNTO and its marketing partner, Wellcome plc, haven't

Read the full 660 word article

How to gain access

Continue reading with a
two-week free trial.